
How a New Family of Drugs Can Work for Alzheimer’s Patients
Clip: Season 8 Episode 38 | 4m 6sVideo has Closed Captions
A new class of drugs targets brain proteins to fight the effects of Alzheimer’s Disease.
A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.
Problems playing video? | Closed Captioning Feedback
Problems playing video? | Closed Captioning Feedback
Nevada Week is a local public television program presented by Vegas PBS

How a New Family of Drugs Can Work for Alzheimer’s Patients
Clip: Season 8 Episode 38 | 4m 6sVideo has Closed Captions
A new family of drugs works to rid Alzheimer’s Disease patients’ brains of the proteins believed to be behind the memory-robbing illness.
Problems playing video? | Closed Captioning Feedback
How to Watch Nevada Week
Nevada Week is available to stream on pbs.org and the free PBS App, available on iPhone, Apple TV, Android TV, Android smartphones, Amazon Fire TV, Amazon Fire Tablet, Roku, Samsung Smart TV, and Vizio.
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship-It is time now for this month's "Your Brain Health Matters."
Right now, there is no cure for Alzheimer's disease.
But pushing back the impact of it, even just a few years, can be really important for patients and their families.
Nevada Week recently visited the UNLV Department of Brain Health, where Dr.
Jeff Cummings explained how a new category of drugs known as anti-amyloid therapies can delay some of the more severe symptoms of Alzheimer's.
And the three approved drugs that you talked about, those drugs do what?
(Dr.
Jeff Cummings) They use the body's own immune system to remove the abnormal protein that accumulates in the brain in Alzheimer's disease.
So there's a cell that keeps germs out of your brain, and we trick that cell into thinking that the protein of Alzheimer's disease is foreign and should be removed.
-So to be clear, they are not cures, those drugs, but they are preventing or they are slowing?
How would you describe what they do?
-They slow the disease by about 30%.
So what we can see is that at the end of an 18-month trial, the patients who received treatment were five months better off than the patients who did not receive treatment.
So if you translate that into several years of therapy, you have more time to drive, more time to be autonomous, more time with the grandchildren, more time to travel, to do all the things you want to do when you're in your later years of life.
-When someone is found to have Alzheimer's, what are the treatments available to them, and what does that process look like?
-When someone is confirmed to have Alzheimer's disease, and you know that we have new blood tests that help us with that process, then one would enter the discussion based on how severe the symptoms were.
If the patients had very mild symptoms, they would-- they would be at least offered these new types of drugs that remove the protein from the brain.
If they were in more advanced stages of the disease, we have drugs, pills, that improve temporarily the memory of the individual involved.
-What side effects exist with these treatments?
-There's one type of side effect that we are particularly concerned with, and that has to do with leaky blood vessels.
As we remove the protein from the brain with the drug, we also remove that same protein from the blood vessel, and that allows it to leak for the first few months after we introduce the drug.
So a few patients develop swelling of the brain and sometimes even blood in the brain through this kind of vessel opening.
And that's why we do several MRIs early in the course, because those vessels heal and therefore that process, that side effect, is limited to the early phase of initiating the therapy.
We can manage that successfully in almost all patients, but only if we monitor it and manage it appropriately.
-Dr.
Cummings says one of the biggest barriers to patients getting these drugs is a lack of knowledge by physicians and also how complex it can be to administer them.
Trials are already underway on the next generation of these drugs, and they aim to cut down the amount of time a patient is required to take them and reduce side effects.
Finding Solutions for Nevada’s Housing Crunch
Video has Closed Captions
Clip: S8 Ep38 | 16m 6s | Nevada’s housing administrator explains a new 2025 legislative bill to boost attainable housing. (16m 6s)
A New Home for Blind and Visually Impaired People in Southern Nevada
Video has Closed Captions
Clip: S8 Ep38 | 5m 28s | The Blind Center of Nevada opens new low-income housing for the blind and visually impaired. (5m 28s)
Providing Support for PBS.org
Learn Moreabout PBS online sponsorship
- News and Public Affairs

Top journalists deliver compelling original analysis of the hour's headlines.

- News and Public Affairs

FRONTLINE is investigative journalism that questions, explains and changes our world.












Support for PBS provided by:
Nevada Week is a local public television program presented by Vegas PBS

